Exelixis, Inc. (EXEL)
USD 36.43
(2.36%)
USD 36.43
(2.36%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 189.94 Million USD | -0.12% |
| 2022 | 190.17 Million USD | 270.9% |
| 2021 | 51.27 Million USD | 4.45% |
| 2020 | 49.08 Million USD | -3.26% |
| 2019 | 50.73 Million USD | 316.64% |
| 2018 | 12.17 Million USD | -16.19% |
| 2017 | 14.53 Million USD | -92.32% |
| 2016 | 189.12 Million USD | -50.42% |
| 2015 | 381.43 Million USD | 5.47% |
| 2014 | 361.65 Million USD | 4.15% |
| 2013 | 347.23 Million USD | 3.43% |
| 2012 | 335.73 Million USD | 84.96% |
| 2011 | 181.51 Million USD | -12.92% |
| 2010 | 208.45 Million USD | 161.83% |
| 2009 | 79.61 Million USD | -32.34% |
| 2008 | 117.68 Million USD | -3.16% |
| 2007 | 121.51 Million USD | -0.11% |
| 2006 | 121.65 Million USD | -18.27% |
| 2005 | 148.84 Million USD | 1.01% |
| 2004 | 147.35 Million USD | 32.65% |
| 2003 | 111.08 Million USD | 50.25% |
| 2002 | 73.93 Million USD | 51.06% |
| 2001 | 48.94 Million USD | 227.38% |
| 2000 | 14.95 Million USD | 12.41% |
| 1999 | 13.3 Million USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 194.44 Million USD | -1.8% |
| 2024 Q1 | 201.46 Million USD | 6.07% |
| 2024 Q2 | 198.01 Million USD | -1.71% |
| 2023 Q3 | 190.85 Million USD | -1.97% |
| 2023 Q4 | 189.94 Million USD | -0.48% |
| 2023 Q2 | 194.69 Million USD | 4.14% |
| 2023 Q1 | 186.94 Million USD | -1.69% |
| 2023 FY | 189.94 Million USD | -0.12% |
| 2022 Q4 | 190.17 Million USD | 18.98% |
| 2022 FY | 190.17 Million USD | 270.9% |
| 2022 Q1 | 50.63 Million USD | -1.24% |
| 2022 Q2 | 161.01 Million USD | 217.99% |
| 2022 Q3 | 159.83 Million USD | -0.73% |
| 2021 Q1 | 52.83 Million USD | 7.64% |
| 2021 Q2 | 53.22 Million USD | 0.73% |
| 2021 FY | 51.27 Million USD | 4.45% |
| 2021 Q4 | 51.27 Million USD | -1.88% |
| 2021 Q3 | 52.25 Million USD | -1.82% |
| 2020 Q3 | 47.62 Million USD | -1.46% |
| 2020 Q4 | 49.08 Million USD | 3.07% |
| 2020 FY | 49.08 Million USD | -3.26% |
| 2020 Q1 | 47.88 Million USD | -5.63% |
| 2020 Q2 | 48.33 Million USD | 0.94% |
| 2019 Q2 | 22.54 Million USD | 12.95% |
| 2019 FY | 50.73 Million USD | 316.64% |
| 2019 Q1 | 19.95 Million USD | 63.89% |
| 2019 Q4 | 50.73 Million USD | 114.04% |
| 2019 Q3 | 23.7 Million USD | 5.15% |
| 2018 Q3 | 12.61 Million USD | -38.88% |
| 2018 FY | 12.17 Million USD | -16.19% |
| 2018 Q4 | 12.17 Million USD | -3.49% |
| 2018 Q2 | 20.64 Million USD | 0.0% |
| 2018 Q1 | - USD | -100.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | 113.34 Million USD | -40.07% |
| 2017 FY | 14.53 Million USD | -92.32% |
| 2017 Q4 | 14.53 Million USD | 0.0% |
| 2017 Q2 | - USD | -100.0% |
| 2016 Q3 | 190.85 Million USD | -51.81% |
| 2016 Q4 | 189.12 Million USD | -0.91% |
| 2016 Q1 | 388.65 Million USD | 1.89% |
| 2016 Q2 | 396.05 Million USD | 1.9% |
| 2016 FY | 189.12 Million USD | -50.42% |
| 2015 Q3 | 377.88 Million USD | 1.79% |
| 2015 Q4 | 381.43 Million USD | 0.94% |
| 2015 Q1 | 368.43 Million USD | 1.87% |
| 2015 FY | 381.43 Million USD | 5.47% |
| 2015 Q2 | 371.22 Million USD | 0.76% |
| 2014 Q1 | 343.01 Million USD | -1.21% |
| 2014 FY | 361.65 Million USD | 4.15% |
| 2014 Q3 | 355.21 Million USD | 1.79% |
| 2014 Q4 | 361.65 Million USD | 1.81% |
| 2014 Q2 | 348.97 Million USD | 1.74% |
| 2013 Q3 | 341.59 Million USD | 1.62% |
| 2013 Q2 | 336.13 Million USD | 1.6% |
| 2013 Q1 | 330.85 Million USD | -1.45% |
| 2013 FY | 347.23 Million USD | 3.43% |
| 2013 Q4 | 347.23 Million USD | 1.65% |
| 2012 FY | 335.73 Million USD | 84.96% |
| 2012 Q1 | 182.06 Million USD | 0.3% |
| 2012 Q2 | 182.69 Million USD | 0.35% |
| 2012 Q3 | 335.29 Million USD | 83.52% |
| 2012 Q4 | 335.73 Million USD | 0.13% |
| 2011 FY | 181.51 Million USD | -12.92% |
| 2011 Q4 | 181.51 Million USD | -13.55% |
| 2011 Q3 | 209.95 Million USD | -0.21% |
| 2011 Q2 | 210.39 Million USD | 1.13% |
| 2011 Q1 | 208.02 Million USD | -0.21% |
| 2010 FY | 208.45 Million USD | 161.83% |
| 2010 Q3 | 234.91 Million USD | -0.52% |
| 2010 Q1 | 76.37 Million USD | -4.08% |
| 2010 Q4 | 208.45 Million USD | -11.26% |
| 2010 Q2 | 236.14 Million USD | 209.21% |
| 2009 Q4 | 79.61 Million USD | -25.2% |
| 2009 Q3 | 106.43 Million USD | -3.32% |
| 2009 FY | 79.61 Million USD | -32.34% |
| 2009 Q2 | 110.09 Million USD | -3.21% |
| 2009 Q1 | 113.75 Million USD | -3.34% |
| 2008 Q3 | 123.37 Million USD | -3.51% |
| 2008 Q4 | 117.68 Million USD | -4.62% |
| 2008 Q1 | 117.88 Million USD | -2.99% |
| 2008 FY | 117.68 Million USD | -3.16% |
| 2008 Q2 | 127.86 Million USD | 8.47% |
| 2007 Q4 | 121.51 Million USD | 8.14% |
| 2007 Q1 | 119.15 Million USD | -2.05% |
| 2007 Q3 | 112.36 Million USD | -2.58% |
| 2007 FY | 121.51 Million USD | -0.11% |
| 2007 Q2 | 115.34 Million USD | -3.2% |
| 2006 Q4 | 121.65 Million USD | 8.14% |
| 2006 FY | 121.65 Million USD | -18.27% |
| 2006 Q3 | 112.49 Million USD | -2.05% |
| 2006 Q2 | 114.84 Million USD | -22.58% |
| 2006 Q1 | 148.33 Million USD | -0.34% |
| 2005 Q1 | 143.01 Million USD | -2.95% |
| 2005 Q2 | 147.27 Million USD | 2.98% |
| 2005 Q4 | 148.84 Million USD | 2.86% |
| 2005 Q3 | 144.71 Million USD | -1.74% |
| 2005 FY | 148.84 Million USD | 1.01% |
| 2004 Q3 | 112.44 Million USD | 5.1% |
| 2004 Q4 | 147.35 Million USD | 31.05% |
| 2004 Q1 | 107.47 Million USD | -3.25% |
| 2004 FY | 147.35 Million USD | 32.65% |
| 2004 Q2 | 106.98 Million USD | -0.46% |
| 2003 Q4 | 111.08 Million USD | 39.71% |
| 2003 FY | 111.08 Million USD | 50.25% |
| 2003 Q1 | 73.75 Million USD | -0.24% |
| 2003 Q2 | 76.21 Million USD | 3.33% |
| 2003 Q3 | 79.51 Million USD | 4.33% |
| 2002 Q4 | 73.93 Million USD | 48.33% |
| 2002 FY | 73.93 Million USD | 51.06% |
| 2002 Q1 | 49.03 Million USD | 0.19% |
| 2002 Q2 | 49.91 Million USD | 1.79% |
| 2002 Q3 | 49.84 Million USD | -0.14% |
| 2001 Q1 | 12.14 Million USD | -18.78% |
| 2001 FY | 48.94 Million USD | 227.38% |
| 2001 Q3 | 50.53 Million USD | 2.73% |
| 2001 Q4 | 48.94 Million USD | -3.15% |
| 2001 Q2 | 49.19 Million USD | 305.13% |
| 2000 Q3 | 10.07 Million USD | -17.42% |
| 2000 Q2 | 12.19 Million USD | -4.54% |
| 2000 Q1 | 12.77 Million USD | 0.0% |
| 2000 Q4 | 14.95 Million USD | 48.42% |
| 2000 FY | 14.95 Million USD | 12.41% |
| 1999 FY | 13.3 Million USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dyadic International, Inc. | 136.92 Thousand USD | -138617.145% |
| Agenus Inc. | 350.24 Million USD | 45.768% |
| AlloVir, Inc. | 27.42 Million USD | -592.493% |
| Ardelyx, Inc. | 55.98 Million USD | -239.295% |
| CASI Pharmaceuticals, Inc. | 21.23 Million USD | -794.317% |
| Chimerix, Inc. | 2.14 Million USD | -8759.328% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -809.509% |
| CRISPR Therapeutics AG | 238.63 Million USD | 20.403% |
| HOOKIPA Pharma Inc. | 6.55 Million USD | -2795.929% |
| Fate Therapeutics, Inc. | 103.53 Million USD | -83.457% |
| Fortress Biotech, Inc. | 88.59 Million USD | -114.403% |
| Fortress Biotech, Inc. | 88.59 Million USD | -114.403% |
| Eton Pharmaceuticals, Inc. | 5.45 Million USD | -3382.016% |
| Hoth Therapeutics, Inc. | 55.16 Thousand USD | -344219.768% |
| Intensity Therapeutics, Inc. | 158 Thousand USD | -120117.722% |
| IO Biotech, Inc. | 2.49 Million USD | -7516.038% |
| Structure Therapeutics Inc. | 5.45 Million USD | -3383.293% |
| Ligand Pharmaceuticals Incorporated | 6.16 Million USD | -2981.006% |
| MiMedx Group, Inc. | 48.09 Million USD | -294.902% |
| Senti Biosciences, Inc. | 37.66 Million USD | -404.285% |
| Opthea Limited | 200.62 Million USD | 5.326% |
| Pharming Group N.V. | 171.54 Million USD | -10.725% |
| Pieris Pharmaceuticals, Inc. | - USD | -Infinity% |
| PureTech Health plc | 25.51 Million USD | -644.528% |
| Rigel Pharmaceuticals, Inc. | 60.57 Million USD | -213.548% |
| Elevation Oncology, Inc. | 30.13 Million USD | -530.268% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -398.488% |
| Madrigal Pharmaceuticals, Inc. | 117.19 Million USD | -62.078% |
| Syros Pharmaceuticals, Inc. | 62.07 Million USD | -205.991% |
| Telomir Pharmaceuticals, Inc. Common Stock | 101 Thousand USD | -187963.366% |
| SELLAS Life Sciences Group, Inc. | 906 Thousand USD | -20865.121% |
| PDS Biotechnology Corporation | 23.85 Million USD | -696.357% |
| Syndax Pharmaceuticals, Inc. | 1.63 Million USD | -11517.37% |
| Entrada Therapeutics, Inc. | 68.23 Million USD | -178.388% |
| Verrica Pharmaceuticals Inc. | 45.51 Million USD | -317.368% |
| Wave Life Sciences Ltd. | 32.11 Million USD | -491.394% |
| Xeris Biopharma Holdings, Inc. | 229.19 Million USD | 17.124% |
| Clearside Biomedical, Inc. | 43 Million USD | -341.72% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Molecular Templates, Inc. | 12.23 Million USD | -1453.099% |
| Sorrento Therapeutics, Inc. | 134.5 Million USD | -41.218% |
| TRACON Pharmaceuticals, Inc. | 968 Thousand USD | -19522.314% |
| Vaxxinity, Inc. | 15.16 Million USD | -1152.268% |
| Viracta Therapeutics, Inc. | 25.55 Million USD | -643.246% |
| Aadi Bioscience, Inc. | 7.02 Million USD | -2604.214% |
| Aptorum Group Limited | 3.36 Million USD | -5549.065% |
| Aridis Pharmaceuticals, Inc. | 6.13 Million USD | -2998.597% |
| IDEAYA Biosciences, Inc. | 2.87 Million USD | -6513.649% |
| Kintara Therapeutics, Inc. | - USD | -Infinity% |
| Akebia Therapeutics, Inc. | 104.18 Million USD | -82.319% |
| ContextLogic Inc. | 6 Million USD | -3065.733% |
| BioXcel Therapeutics, Inc. | 101.38 Million USD | -87.351% |
| C4 Therapeutics, Inc. | 70.97 Million USD | -167.617% |
| ESSA Pharma Inc. | 80.32 Thousand USD | -236360.512% |
| Pyxis Oncology, Inc. | 21.33 Million USD | -790.46% |
| Royalty Pharma plc | 6.13 Billion USD | 96.904% |
| Inhibrx Biosciences, Inc. | 210.14 Million USD | 9.611% |
| TG Therapeutics, Inc. | 110.79 Million USD | -71.437% |
| Outlook Therapeutics, Inc. | 35.55 Million USD | -434.222% |
| Janux Therapeutics, Inc. | 24.54 Million USD | -673.955% |
| TransCode Therapeutics, Inc. | 450.57 Thousand USD | -42056.286% |
| Seer, Inc. | 28.25 Million USD | -572.154% |
| MEI Pharma, Inc. | - USD | -Infinity% |
| Salarius Pharmaceuticals, Inc. | 289.64 Thousand USD | -65478.661% |
| NextCure, Inc. | 6.6 Million USD | -2775.761% |
| Oncternal Therapeutics, Inc. | 318 Thousand USD | -59630.818% |
| VistaGen Therapeutics, Inc. | 2.12 Million USD | -8859.623% |
| Phathom Pharmaceuticals, Inc. | 139.03 Million USD | -36.621% |
| AnaptysBio, Inc. | 17.81 Million USD | -966.262% |
| ChromaDex Corporation | 3.27 Million USD | -5696.277% |
| Precigen, Inc. | 7.09 Million USD | -2576.398% |
| CARGO Therapeutics, Inc. Common Stock | 28.54 Million USD | -565.513% |
| Caribou Biosciences, Inc. | 27.48 Million USD | -591.082% |
| Sol-Gel Technologies Ltd. | 1.65 Million USD | -11390.865% |
| Acelyrin, Inc. | 1.19 Million USD | -15808.208% |
| Sensei Biotherapeutics, Inc. | 6.2 Million USD | -2959.665% |
| Psyence Biomedical Ltd. | 7.65 Million USD | -2380.53% |
| Keros Therapeutics, Inc. | 14.44 Million USD | -1215.037% |
| Lantern Pharma Inc. | 234.47 Thousand USD | -80909.592% |
| Barinthus Biotherapeutics plc | 12.97 Million USD | -1363.81% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Titan Pharmaceuticals, Inc. | 565 Thousand USD | -33518.407% |
| AbCellera Biologics Inc. | 77.38 Million USD | -145.469% |
| Alnylam Pharmaceuticals, Inc. | 2.68 Billion USD | 92.919% |
| Bicycle Therapeutics plc | 44.95 Million USD | -322.511% |
| GlycoMimetics, Inc. | 808.4 Thousand USD | -23396.231% |
| Incyte Corporation | 38.28 Million USD | -396.106% |
| Alkermes plc | 290.73 Million USD | 34.667% |
| Orchestra BioMed Holdings, Inc. | 1.68 Million USD | -11159.277% |
| Ocuphire Pharma, Inc. | - USD | -Infinity% |
| Onconetix, Inc. | 9.88 Million USD | -1821.388% |
| Avidity Biosciences, Inc. | 9.85 Million USD | -1827.974% |
| Geron Corporation | 85.89 Million USD | -121.125% |
| Summit Therapeutics Inc. | 106.09 Million USD | -79.025% |
| Stoke Therapeutics, Inc. | 6.83 Million USD | -2678.99% |
| Alaunos Therapeutics, Inc. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 16.83 Million USD | -1028.604% |
| Inhibikase Therapeutics, Inc. | 622 Thousand USD | -30437.473% |
| Innoviva, Inc. | 449.07 Million USD | 57.703% |
| Jaguar Health, Inc. | 35.86 Million USD | -429.682% |
| Longboard Pharmaceuticals, Inc. | 475 Thousand USD | -39888.211% |
| Marinus Pharmaceuticals, Inc. | 110.35 Million USD | -72.116% |
| Vaxcyte, Inc. | 29.22 Million USD | -549.959% |
| ADMA Biologics, Inc. | 141.41 Million USD | -34.314% |
| Arrowhead Pharmaceuticals, Inc. | 115.17 Million USD | -64.923% |
| VYNE Therapeutics Inc. | 214 Thousand USD | -88658.879% |
| Novavax, Inc. | 280.63 Million USD | 32.316% |
| eFFECTOR Therapeutics, Inc. | 19.44 Million USD | -876.827% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Alzamend Neuro, Inc. | 300.71 Thousand USD | -63064.336% |
| Compass Therapeutics, Inc. | 1.73 Million USD | -10860.415% |
| Catalyst Pharmaceuticals, Inc. | 3.55 Million USD | -5240.006% |
| Precision BioSciences, Inc. | 31.26 Million USD | -507.471% |
| GT Biopharma, Inc. | 58 Thousand USD | -327389.655% |
| ImmuCell Corporation | 11.96 Million USD | -1486.926% |
| Immix Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 118.92 Million USD | -59.72% |
| Rocket Pharmaceuticals, Inc. | 25.04 Million USD | -658.502% |
| Aptose Biosciences Inc. | 1 Million USD | -18709.95% |
| ZyVersa Therapeutics, Inc. | 8656.00 USD | -2194262.292% |
| Soligenix, Inc. | 3.49 Million USD | -5335.418% |
| Century Therapeutics, Inc. | 48.17 Million USD | -294.312% |
| Kura Oncology, Inc. | 17.2 Million USD | -1004.326% |
| TScan Therapeutics, Inc. | 92.43 Million USD | -105.494% |
| Ocean Biomedical, Inc. | 2.15 Million USD | -8734.605% |
| CytomX Therapeutics, Inc. | 13.97 Million USD | -1259.267% |
| Autolus Therapeutics plc | 52.96 Million USD | -258.608% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| EyePoint Pharmaceuticals, Inc. | 5.46 Million USD | -3373.103% |
| Eterna Therapeutics Inc. | 41.84 Million USD | -353.945% |
| Adaptive Biotechnologies Corporation | 229.43 Million USD | 17.211% |
| GRI Bio, Inc. | 14 Thousand USD | -1356642.857% |
| Xenetic Biosciences, Inc. | - USD | -Infinity% |
| Tenaya Therapeutics, Inc. | 12.42 Million USD | -1428.847% |
| IGM Biosciences, Inc. | 40.5 Million USD | -368.928% |
| INmune Bio, Inc. | 10.43 Million USD | -1719.91% |
| Heron Therapeutics, Inc. | 179.62 Million USD | -5.743% |
| SAB Biotherapeutics, Inc. | 5.9 Million USD | -3115.543% |
| Pasithea Therapeutics Corp. | 81.68 Thousand USD | -232446.523% |
| Entero Therapeutics, Inc. | 826.84 Thousand USD | -22872.169% |
| Milestone Pharmaceuticals Inc. | 51.77 Million USD | -266.864% |
| X4 Pharmaceuticals, Inc. | 58.28 Million USD | -225.911% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -228.214% |
| Coherus BioSciences, Inc. | 480.84 Million USD | 60.498% |
| Verastem, Inc. | 41.55 Million USD | -357.069% |
| Abeona Therapeutics Inc. | 5.4 Million USD | -3417.481% |
| Pliant Therapeutics, Inc. | 11.37 Million USD | -1570.278% |
| Tonix Pharmaceuticals Holding Corp. | 9.81 Million USD | -1835.636% |
| Histogen Inc. | 4.62 Million USD | -4009.563% |
| Aprea Therapeutics, Inc. | - USD | -Infinity% |
| Surrozen, Inc. | 3.37 Million USD | -5521.308% |
| Organovo Holdings, Inc. | 1.39 Million USD | -13525.825% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Ovid Therapeutics Inc. | 46 Million USD | -312.906% |
| Panbela Therapeutics, Inc. | 5.19 Million USD | -3556.989% |
| Cadrenal Therapeutics, Inc. Common Stock | 21.35 Thousand USD | -889567.447% |
| Centessa Pharmaceuticals plc | 84.58 Million USD | -124.552% |
| Hepion Pharmaceuticals, Inc. | 209.02 Thousand USD | -90773.601% |
| Arcturus Therapeutics Holdings Inc. | 30.21 Million USD | -528.621% |
| BioRestorative Therapies, Inc. | 162.31 Thousand USD | -116920.398% |
| Apollomics, Inc. | 4.66 Million USD | -3975.177% |
| Amarin Corporation plc | 8.73 Million USD | -2074.019% |
| Turnstone Biologics Corp. | 3.21 Million USD | -5809.894% |
| Kymera Therapeutics, Inc. | 84.67 Million USD | -124.324% |
| Synaptogenix, Inc. | - USD | -Infinity% |
| Tiziana Life Sciences Ltd | 247 Thousand USD | -76800.405% |
| Aurinia Pharmaceuticals Inc. | 97.6 Million USD | -94.601% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Better Therapeutics, Inc. | 14.88 Million USD | -1176.505% |
| Nurix Therapeutics, Inc. | 30.61 Million USD | -520.448% |
| Apellis Pharmaceuticals, Inc. | 110.92 Million USD | -71.232% |
| NLS Pharmaceutics AG | 1.63 Million USD | -11526.287% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Gritstone bio, Inc. | 104.77 Million USD | -81.288% |
| Jasper Therapeutics, Inc. | 2.78 Million USD | -6717.803% |
| TNF Pharmaceuticals, Inc. | 48.87 Thousand USD | -388571.987% |
| Avid Bioservices, Inc. | 207.83 Million USD | 8.608% |
| Insmed Incorporated | 1.2 Billion USD | 84.224% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| MediWound Ltd. | 6.71 Million USD | -2730.338% |
| OmniAb, Inc. | 25.56 Million USD | -643.101% |
| Alector, Inc. | 38.91 Million USD | -388.062% |
| Seres Therapeutics, Inc. | 213.93 Million USD | 11.215% |
| Checkpoint Therapeutics, Inc. | - USD | -Infinity% |
| Zai Lab Limited | 15.15 Million USD | -1153.673% |
| Revance Therapeutics, Inc. | 478.43 Million USD | 60.299% |
| Aura Biosciences, Inc. | 19.55 Million USD | -871.233% |
| Lyell Immunopharma, Inc. | 63.16 Million USD | -200.701% |
| Immunic, Inc. | 1.33 Million USD | -14138.681% |
| Tarsus Pharmaceuticals, Inc. | 31.73 Million USD | -498.588% |
| Veracyte, Inc. | 12.63 Million USD | -1403.911% |
| InMed Pharmaceuticals Inc. | 644.86 Million USD | 70.545% |
| FibroGen, Inc. | 170.45 Million USD | -11.434% |
| SeaStar Medical Holding Corporation | 9.08 Million USD | -1991.664% |
| Adial Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sonnet BioTherapeutics Holdings, Inc. | 203.91 Thousand USD | -93050.443% |
| Jazz Pharmaceuticals plc | 5.79 Billion USD | 96.723% |
| Cyclacel Pharmaceuticals, Inc. | 37 Thousand USD | -513262.162% |
| Amylyx Pharmaceuticals, Inc. | 4.23 Million USD | -4382.983% |
| Galecto, Inc. | 249 Thousand USD | -76182.731% |
| Calithera Biosciences, Inc. | 1.66 Million USD | -11301.2% |
| Fortrea Holdings Inc. | 1.67 Billion USD | 88.68% |
| KalVista Pharmaceuticals, Inc. | 7.31 Million USD | -2495.927% |
| Aptevo Therapeutics Inc. | 5.39 Million USD | -3419.437% |
| XBiotech Inc. | - USD | -Infinity% |
| Jasper Therapeutics, Inc. | 2.78 Million USD | -6717.803% |
| Lyra Therapeutics, Inc. | 26.88 Million USD | -606.611% |
| Foghorn Therapeutics Inc. | 45.07 Million USD | -321.414% |
| Y-mAbs Therapeutics, Inc. | 1.41 Million USD | -13285.765% |
| Theravance Biopharma, Inc. | 45.23 Million USD | -319.896% |
| Ultragenyx Pharmaceutical Inc. | 43.16 Million USD | -340.001% |
| Metagenomi, Inc. Common Stock | 48.22 Million USD | -293.838% |
| BioCryst Pharmaceuticals, Inc. | 848.71 Million USD | 77.62% |
| Gain Therapeutics, Inc. | 1.02 Million USD | -18387.869% |
| Cartesian Therapeutics, Inc. | 10.95 Million USD | -1633.857% |
| NexImmune, Inc. | 68.8 Thousand USD | -275945.285% |
| Creative Medical Technology Holdings, Inc. | 14.19 Thousand USD | -1338099.239% |
| Marker Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 92.973% |
| Chemomab Therapeutics Ltd. | 392 Thousand USD | -48354.855% |
| RAPT Therapeutics, Inc. | 6.9 Million USD | -2650.42% |
| Ainos, Inc. | 5.96 Million USD | -3085.08% |
| Pluri Inc. | 29.61 Million USD | -541.443% |
| Prothena Corporation plc | 11.83 Million USD | -1504.935% |
| Adaptimmune Therapeutics plc | 25.23 Million USD | -652.701% |
| Celularity Inc. | 65.41 Million USD | -190.359% |
| Rallybio Corporation | 392 Thousand USD | -48355.102% |
| Cue Biopharma, Inc. | 14.69 Million USD | -1192.576% |
| MeiraGTx Holdings plc | 89.26 Million USD | -112.789% |
| Omeros Corporation | 338.28 Million USD | 43.85% |
| Humacyte, Inc. | 58.1 Million USD | -226.892% |
| Immunocore Holdings plc | 84.03 Million USD | -126.038% |
| Cocrystal Pharma, Inc. | 1.85 Million USD | -10150.621% |
| Cidara Therapeutics, Inc. | 4.87 Million USD | -3794.689% |
| Blueprint Medicines Corporation | 774.12 Million USD | 75.463% |
| CalciMedica, Inc. | - USD | -Infinity% |
| Cabaletta Bio, Inc. | 5.01 Million USD | -3685.253% |
| Scholar Rock Holding Corporation | 61.81 Million USD | -207.263% |
| Sana Biotechnology, Inc. | 104.09 Million USD | -82.47% |
| Pulmatrix, Inc. | 8.75 Million USD | -2069.301% |
| Elicio Therapeutics, Inc. | 6.91 Million USD | -2646.046% |
| Vigil Neuroscience, Inc. | 13.85 Million USD | -1271.437% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -64.673% |
| Adlai Nortye Ltd. American Depositary Shares | 31.54 Million USD | -502.079% |
| Cytokinetics, Incorporated | 755.77 Million USD | 74.868% |
| Eloxx Pharmaceuticals, Inc. | 13.38 Million USD | -1319.187% |
| Nutriband Inc. | 241.28 Thousand USD | -78621.843% |
| Protara Therapeutics, Inc. | 5.46 Million USD | -3374.374% |
| Vor Biopharma Inc. | 35.66 Million USD | -432.653% |
| Roivant Sciences Ltd. | 499.74 Million USD | 61.992% |
| Evogene Ltd. | 1.13 Million USD | -16591.037% |
| ProKidney Corp. | 4.41 Million USD | -4204.192% |
| Applied Therapeutics, Inc. | 1.22 Million USD | -15392.985% |
| BridgeBio Pharma, Inc. | 1.73 Billion USD | 89.083% |
| CorMedix Inc. | 667.63 Thousand USD | -28350.404% |
| BioLineRx Ltd. | 11.59 Million USD | -1538.72% |
| Tango Therapeutics, Inc. | 38.92 Million USD | -388.037% |
| Galectin Therapeutics Inc. | 71.8 Million USD | -164.52% |
| Atai Life Sciences N.V. | 16.47 Million USD | -1052.853% |
| Renovaro Biosciences Inc. | 2.45 Million USD | -7649.666% |
| Aerovate Therapeutics, Inc. | 675 Thousand USD | -28039.852% |
| Zentalis Pharmaceuticals, Inc. | 45.77 Million USD | -314.97% |
| Sagimet Biosciences Inc. | 65 Thousand USD | -292121.538% |
| MediciNova, Inc. | 215.92 Thousand USD | -87867.174% |
| Praxis Precision Medicines, Inc. | 2.49 Million USD | -7512.986% |
| Cardio Diagnostics Holdings, Inc. | 1.26 Million USD | -14962.631% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -1.917% |
| Biomea Fusion, Inc. | 10.29 Million USD | -1744.833% |
| PTC Therapeutics, Inc. | 415.02 Million USD | 54.233% |
| Mereo BioPharma Group plc | 5.95 Million USD | -3091.263% |
| Cullinan Oncology, Inc. | 3.59 Million USD | -5190.919% |
| Absci Corporation | 15.95 Million USD | -1090.349% |
| NRx Pharmaceuticals, Inc. | 9.16 Million USD | -1973.398% |
| 4D Molecular Therapeutics, Inc. | 14.67 Million USD | -1194.69% |
| Dyne Therapeutics, Inc. | 27.41 Million USD | -592.847% |
| Kiniksa Pharmaceuticals, Ltd. | 12.25 Million USD | -1449.551% |
| Ventyx Biosciences, Inc. | 12.5 Million USD | -1418.823% |
| Allakos Inc. | 41.46 Million USD | -358.083% |
| Imunon, Inc. | 1.62 Million USD | -11590.919% |
| Fulcrum Therapeutics, Inc. | 10.82 Million USD | -1655.328% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -125690.728% |
| BioAtla, Inc. | 2.46 Million USD | -7621.301% |
| NLS Pharmaceutics AG | 1.63 Million USD | -11526.287% |
| Bio-Path Holdings, Inc. | 113 Thousand USD | -167992.035% |
| Allogene Therapeutics, Inc. | 95.12 Million USD | -99.687% |
| Larimar Therapeutics, Inc. | 5.54 Million USD | -3324.883% |
| XOMA Corporation | 124.45 Million USD | -52.627% |
| Kezar Life Sciences, Inc. | 18.93 Million USD | -903.243% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -340.021% |
| aTyr Pharma, Inc. | 15.09 Million USD | -1158.324% |
| Aligos Therapeutics, Inc. | 11.13 Million USD | -1605.369% |
| Akero Therapeutics, Inc. | 26.04 Million USD | -629.348% |
| Viridian Therapeutics, Inc. | 21.04 Million USD | -802.433% |
| Eliem Therapeutics, Inc. | 349 Thousand USD | -54325.215% |
| EyeGate Pharmaceuticals, Inc. | 326.49 Thousand USD | -58077.051% |
| Akari Therapeutics, Plc | - USD | -Infinity% |
| Tevogen Bio Holdings Inc. | 1.63 Million USD | -11540.687% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 87.331% |
| Lexaria Bioscience Corp. | 163.96 Thousand USD | -115742.822% |
| UroGen Pharma Ltd. | 100.21 Million USD | -89.538% |
| Sutro Biopharma, Inc. | 182.74 Million USD | -3.937% |
| ZIVO Bioscience, Inc. | 346.34 Thousand USD | -54742.901% |
| Orgenesis Inc. | 22.62 Million USD | -739.68% |
| Entera Bio Ltd. | 390 Thousand USD | -48603.59% |
| GH Research PLC | 343 Thousand USD | -55277.259% |
| Lisata Therapeutics, Inc. | 305 Thousand USD | -62176.721% |
| Reneo Pharmaceuticals, Inc. | 973 Thousand USD | -19421.48% |
| Xencor, Inc. | 83.43 Million USD | -127.658% |
| 60 Degrees Pharmaceuticals, Inc. | 172.67 Thousand USD | -109902.143% |
| Replimune Group, Inc. | 75.86 Million USD | -150.358% |
| Coeptis Therapeutics Holdings, Inc. | 1.22 Million USD | -15415.436% |
| Vanda Pharmaceuticals Inc. | 9.4 Million USD | -1919.821% |
| Lexaria Bioscience Corp. | 163.96 Thousand USD | -115742.822% |
| Portage Biotech Inc. | 47 Thousand USD | -404036.17% |
| Cardio Diagnostics Holdings, Inc. | 1.26 Million USD | -14962.631% |
| Olema Pharmaceuticals, Inc. | 2.41 Million USD | -7758.668% |
| OncoCyte Corporation | 2.86 Million USD | -6520.565% |
| Qualigen Therapeutics, Inc. | 1.29 Million USD | -14519.894% |
| Processa Pharmaceuticals, Inc. | 150.55 Thousand USD | -126063.37% |
| Purple Biotech Ltd. | 351 Thousand USD | -54015.1% |
| CollPlant Biotechnologies Ltd. | 3.15 Million USD | -5912.789% |
| scPharmaceuticals Inc. | 40.26 Million USD | -371.688% |
| ProMIS Neurosciences, Inc. | - USD | -Infinity% |
| HilleVax, Inc. | 51.19 Million USD | -271.035% |
| NeuroSense Therapeutics Ltd. | 142 Thousand USD | -133663.38% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | - USD | -Infinity% |
| Neumora Therapeutics, Inc. Common Stock | 5.23 Million USD | -3531.122% |
| Atossa Therapeutics, Inc. | - USD | -Infinity% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | - USD | -Infinity% |
| Savara Inc. | 26.73 Million USD | -610.39% |
| Curis, Inc. | 2.79 Million USD | -6698.282% |
| Daré Bioscience, Inc. | 5.31 Million USD | -3471.621% |
| Carmell Therapeutics Corporation | 2.13 Million USD | -8790.64% |
| Achieve Life Sciences, Inc. | 16.73 Million USD | -1035.282% |
| BeiGene, Ltd. | 930.18 Million USD | 79.58% |
| Kiromic BioPharma, Inc. | 15.54 Million USD | -1122.094% |
| Revolution Medicines, Inc. Warrant | 87.94 Million USD | -115.983% |
| Protagonist Therapeutics, Inc. | 1.14 Million USD | -16547.152% |
| Erasca, Inc. | 55.85 Million USD | -240.042% |
| bluebird bio, Inc. | 330.32 Million USD | 42.498% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 83.248% |
| DBV Technologies S.A. | 14.38 Million USD | -1220.798% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Moderna, Inc. | - USD | -Infinity% |
| Vincerx Pharma, Inc. | 2.5 Million USD | -7491.687% |
| Fresh Tracks Therapeutics, Inc. | - USD | -Infinity% |
| Acrivon Therapeutics, Inc. Common Stock | 4.64 Million USD | -3990.095% |
| Travere Therapeutics, Inc. | 404.78 Million USD | 53.075% |
| Monte Rosa Therapeutics, Inc. | 46.03 Million USD | -312.572% |
| Spruce Biosciences, Inc. | 4.6 Million USD | -4021.154% |
| Celldex Therapeutics, Inc. | 2.54 Million USD | -7372.227% |
| Cogent Biosciences, Inc. | 18.85 Million USD | -907.5% |
| MacroGenics, Inc. | 33.97 Million USD | -459.136% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | 20.92 Million USD | -807.781% |
| Prime Medicine, Inc. | 13.63 Million USD | -1293.266% |
| Aditxt, Inc. | 18.21 Million USD | -942.618% |
| Adagene Inc. | 22.3 Million USD | -751.504% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 15.3 Million USD | -1141.221% |
| Maravai LifeSciences Holdings, Inc. | 610.96 Million USD | 68.911% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 20.29 Million USD | -836.007% |
| SciSparc Ltd. | 76 Thousand USD | -249826.316% |
| Vericel Corporation | 88.14 Million USD | -115.495% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Minerva Neurosciences, Inc. | 82.01 Million USD | -131.592% |
| Generation Bio Co. | 97.89 Million USD | -94.03% |
| Astria Therapeutics, Inc. | 329 Thousand USD | -57633.739% |
| Black Diamond Therapeutics, Inc. | 25.29 Million USD | -650.826% |
| Arcutis Biotherapeutics, Inc. | 205.91 Million USD | 7.757% |
| Invivyd, Inc. | 2.16 Million USD | -8673.395% |
| Relay Therapeutics, Inc. | 53.46 Million USD | -255.261% |
| Quoin Pharmaceuticals, Ltd. | 3523.73 USD | -5390324.351% |
| Spero Therapeutics, Inc. | 5.54 Million USD | -3326.736% |
| Artelo Biosciences, Inc. | 63 Thousand USD | -301398.413% |
| 2seventy bio, Inc. | 256.67 Million USD | 25.998% |
| Clene Inc. | 32.16 Million USD | -490.604% |
| Capricor Therapeutics, Inc. | 5.61 Million USD | -3284.512% |
| Boundless Bio, Inc. Common Stock | 2.19 Million USD | -8553.485% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Recursion Pharmaceuticals, Inc. | 50.67 Million USD | -274.85% |
| Citius Pharmaceuticals, Inc. | 481.24 Thousand USD | -39369.293% |
| Contineum Therapeutics, Inc. Class A Common Stock | 193.19 Million USD | 1.681% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| Finch Therapeutics Group, Inc. | 30.12 Million USD | -530.499% |
| ALX Oncology Holdings Inc. | 17.19 Million USD | -1004.518% |
| Vir Biotechnology, Inc. | 124.54 Million USD | -52.516% |
| Evaxion Biotech A/S | 10.86 Million USD | -1647.467% |
| Ocular Therapeutix, Inc. | 83.38 Million USD | -127.781% |
| Verve Therapeutics, Inc. | 74.9 Million USD | -153.573% |
| Trevena, Inc. | 35.23 Million USD | -439.108% |
| Surrozen, Inc. | 3.37 Million USD | -5521.308% |
| Tyra Biosciences, Inc. | 6.49 Million USD | -2824.015% |
| Cingulate Inc. | 3.13 Million USD | -5958.628% |
| Galmed Pharmaceuticals Ltd. | 41 Thousand USD | -463178.049% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -603.757% |
| Tenax Therapeutics, Inc. | 500.9 Thousand USD | -37820.316% |
| Terns Pharmaceuticals, Inc. | 603 Thousand USD | -31399.834% |
| ACADIA Pharmaceuticals Inc. | 57.2 Million USD | -232.041% |
| Connect Biopharma Holdings Limited | 465 Thousand USD | -40748.172% |
| Clearmind Medicine Inc. | - USD | -Infinity% |
| Kronos Bio, Inc. | 28.27 Million USD | -571.845% |
| Bolt Biotherapeutics, Inc. | 20.21 Million USD | -839.433% |
| CERo Therapeutics Holdings, Inc. | 1.55 Million USD | -12115.048% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -14974.921% |
| Statera Biopharma, Inc. | 16.26 Million USD | -1068.086% |
| ImmunityBio, Inc. | 883.67 Million USD | 78.505% |
| Korro Bio, Inc. | 33.2 Million USD | -472.0% |
| Kineta, Inc. | 1.31 Million USD | -14322.475% |
| BioVie Inc. | 6.11 Million USD | -3008.004% |
| Codexis, Inc. | 22.36 Million USD | -749.329% |
| Celularity Inc. | 65.41 Million USD | -190.359% |
| Crinetics Pharmaceuticals, Inc. | 51.72 Million USD | -267.198% |
| Celcuity Inc. | 37.44 Million USD | -407.244% |
| Virax Biolabs Group Limited | 224.3 Thousand USD | -84583.014% |
| Cibus, Inc. | 24.62 Million USD | -671.472% |
| Eledon Pharmaceuticals, Inc. | 383 Thousand USD | -49493.734% |
| IN8bio, Inc. | 4.89 Million USD | -3781.954% |
| Kodiak Sciences Inc. | 181.63 Million USD | -4.576% |
| Annexon, Inc. | 31.35 Million USD | -505.785% |
| Adverum Biotechnologies, Inc. | 75.03 Million USD | -153.137% |
| Assembly Biosciences, Inc. | 2.34 Million USD | -8010.333% |
| Avalo Therapeutics, Inc. | 3.9 Million USD | -4766.615% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 86.932% |
| Eyenovia, Inc. | 16.1 Million USD | -1079.208% |
| Puma Biotechnology, Inc. | 111.49 Million USD | -70.369% |
| Conduit Pharmaceuticals Inc. | 985 Thousand USD | -19183.655% |
| Xilio Therapeutics, Inc. | 11.45 Million USD | -1557.886% |
| Arcellx, Inc. | 97.62 Million USD | -94.565% |
| Cardiff Oncology, Inc. | 2.14 Million USD | -8738.716% |
| Enanta Pharmaceuticals, Inc. | 26.51 Million USD | -616.418% |
| Regulus Therapeutics Inc. | 3.1 Million USD | -6023.275% |
| Moolec Science SA | 2.64 Million USD | -7080.463% |
| Acumen Pharmaceuticals, Inc. | 28.48 Million USD | -566.774% |
| LAVA Therapeutics N.V. | 6.31 Million USD | -2908.776% |
| Atea Pharmaceuticals, Inc. | 2.4 Million USD | -7807.744% |
| Greenwich LifeSciences, Inc. | - USD | -Infinity% |
| TFF Pharmaceuticals, Inc. | 115.25 Thousand USD | -164704.692% |
| Mersana Therapeutics, Inc. | 33.83 Million USD | -461.466% |
| Humacyte, Inc. | 58.1 Million USD | -226.892% |
| 89bio, Inc. | 27.1 Million USD | -600.694% |
| PMV Pharmaceuticals, Inc. | 13.28 Million USD | -1329.655% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | 2.51 Million USD | -7440.453% |
| Trevi Therapeutics, Inc. | 1.33 Million USD | -14096.114% |
| Lexicon Pharmaceuticals, Inc. | 106.06 Million USD | -79.084% |
| Notable Labs, Ltd. | 2.04 Million USD | -9170.083% |
| Liquidia Corporation | 3.5 Million USD | -5322.324% |
| Mustang Bio, Inc. | 2.49 Million USD | -7503.843% |
| Immunovant, Inc. | 138 Thousand USD | -137540.58% |
| Quantum-Si incorporated | 15.3 Million USD | -1141.221% |
| Arbutus Biopharma Corporation | 8.72 Million USD | -2078.007% |
| DiaMedica Therapeutics Inc. | 400 Thousand USD | -47386.0% |
| Vera Therapeutics, Inc. | 53.7 Million USD | -253.661% |
| Acasti Pharma Inc. | - USD | -Infinity% |
| MiNK Therapeutics, Inc. | - USD | -Infinity% |
| Pasithea Therapeutics Corp. | 81.68 Thousand USD | -232446.523% |
| Xenon Pharmaceuticals Inc. | 10.9 Million USD | -1642.126% |
| Elevai Labs, Inc. Common Stock | 210.48 Thousand USD | -90139.395% |
| NeuroBo Pharmaceuticals, Inc. | 203 Thousand USD | -93468.473% |
| Tempest Therapeutics, Inc. | 20.66 Million USD | -819.336% |
| Soleno Therapeutics, Inc. | 403 Thousand USD | -47032.506% |
| PepGen Inc. | 20.1 Million USD | -844.807% |
| Moleculin Biotech, Inc. | 574 Thousand USD | -32991.289% |
| United Therapeutics Corporation | 700 Million USD | 72.865% |
| Nuvectis Pharma, Inc. | - USD | -Infinity% |
| Solid Biosciences Inc. | 26.26 Million USD | -623.183% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Immuneering Corporation | 4.46 Million USD | -4156.01% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | - USD | -Infinity% |
| Belite Bio, Inc | 886 Thousand USD | -21338.375% |
| XOMA Corporation | 124.45 Million USD | -52.627% |
| ARS Pharmaceuticals, Inc. | 274 Thousand USD | -69222.628% |
| Bionomics Limited | 239.61 Million USD | 20.73% |
| Apogee Therapeutics, Inc. | 2.03 Million USD | -9238.451% |
| Alpha Tau Medical Ltd. | 13.27 Million USD | -1330.732% |
| uniQure N.V. | 138.4 Million USD | -37.234% |
| Cassava Sciences, Inc. | - USD | -Infinity% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | 85.42 Million USD | -122.357% |
| Forte Biosciences, Inc. | - USD | -Infinity% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | 1.03 Million USD | -18305.426% |
| Conduit Pharmaceuticals Inc. | 985 Thousand USD | -19183.655% |
| SeaStar Medical Holding Corporation | 9.08 Million USD | -1991.664% |
| FibroBiologics, Inc. Common Stock | 1.74 Million USD | -10772.582% |
| Altimmune, Inc. | 671 Thousand USD | -28207.601% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 57.322% |
| Alpha Tau Medical Ltd. | 13.27 Million USD | -1330.732% |
| Compugen Ltd. | 1.35 Million USD | -13959.511% |
| Peak Bio, Inc. | 10.72 Million USD | -1671.567% |
| Zevra Therapeutics, Inc. | 42.76 Million USD | -344.147% |
| Benitec Biopharma Inc. | 284 Thousand USD | -66781.69% |
| Spyre Therapeutics, Inc. | 84.55 Million USD | -124.64% |
| NKGen Biotech, Inc. Common Stock | 19.92 Million USD | -853.486% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | 11.77 Million USD | -1512.565% |
| Aileron Therapeutics, Inc. | 91.45 Million USD | -107.684% |
| NKGen Biotech, Inc. Warrants | 19.92 Million USD | -853.486% |
| Instil Bio, Inc. | 86.05 Million USD | -120.727% |
| argenx SE | 20 Million USD | -849.72% |
| Immunome, Inc. | 1.65 Million USD | -11411.758% |
| Verona Pharma plc | 51.32 Million USD | -270.052% |
| enGene Holdings Inc. Warrants | 9.77 Million USD | -1842.565% |
| Shattuck Labs, Inc. | 4.2 Million USD | -4420.324% |
| CervoMed Inc. | - USD | -Infinity% |
| LENZ Therapeutics, Inc. | 362 Thousand USD | -52370.718% |
| Plus Therapeutics, Inc. | 4.18 Million USD | -4443.028% |
| Dianthus Therapeutics, Inc. | 585 Thousand USD | -32369.06% |
| Moolec Science SA | 2.64 Million USD | -7080.463% |
| Enveric Biosciences, Inc. | - USD | -Infinity% |
| Inovio Pharmaceuticals, Inc. | 30.2 Million USD | -528.761% |
| Design Therapeutics, Inc. | 3.05 Million USD | -6127.672% |
| Leap Therapeutics, Inc. | 262 Thousand USD | -72397.71% |
| NeurAxis, Inc. | 224.26 Thousand USD | -84598.118% |
| Seelos Therapeutics, Inc. | 14.22 Million USD | -1235.001% |
| Lumos Pharma, Inc. | 6.58 Million USD | -2784.495% |
| Achilles Therapeutics plc | 4.61 Million USD | -4015.796% |
| enGene Holdings Inc. Common Stock | 9.77 Million USD | -1842.565% |
| 180 Life Sciences Corp. | 1.32 Million USD | -14288.945% |
| Opiant Pharmaceuticals, Inc. | 17.08 Million USD | -1012.076% |
| CERo Therapeutics Holdings, Inc. | 1.55 Million USD | -12115.048% |
| Nutriband Inc. | 241.28 Thousand USD | -78621.843% |
| ORIC Pharmaceuticals, Inc. | 10.21 Million USD | -1759.826% |
| CG Oncology, Inc. Common stock | 826 Thousand USD | -22895.642% |
| Fractyl Health, Inc. Common Stock | 373.72 Million USD | 49.175% |
| Rani Therapeutics Holdings, Inc. | 30.09 Million USD | -531.064% |
| MoonLake Immunotherapeutics | 3.69 Million USD | -5036.584% |
| Palisade Bio, Inc. | 369 Thousand USD | -51375.339% |
| Tourmaline Bio, Inc. | 415 Thousand USD | -45669.639% |
| Beam Therapeutics Inc. | 173.17 Million USD | -9.685% |
| Neurogene Inc. | 16.25 Million USD | -1068.527% |
| Mirum Pharmaceuticals, Inc. | 308.14 Million USD | 38.358% |
| AEON Biopharma, Inc. | 278 Thousand USD | -68225.18% |
| Sesen Bio, Inc. | - USD | -Infinity% |
| Enliven Therapeutics, Inc. | 335 Thousand USD | -56599.701% |
| Kiora Pharmaceuticals, Inc. | 106.89 Thousand USD | -177598.777% |
| Iovance Biotherapeutics, Inc. | 75.86 Million USD | -150.381% |
| Taysha Gene Therapies, Inc. | 61.1 Million USD | -210.838% |
| Athira Pharma, Inc. | 1.58 Million USD | -11883.849% |
| Vaccinex, Inc. | 247 Thousand USD | -76800.405% |
| HCW Biologics Inc. | 6.45 Million USD | -2844.057% |
| XOMA Corporation | 124.45 Million USD | -52.627% |
| Nektar Therapeutics | 230.4 Million USD | 17.559% |
| Arvinas, Inc. | 3.4 Million USD | -5486.588% |
| Tevogen Bio Holdings Inc. | 1.63 Million USD | -11540.687% |
| Merus N.V. | 12.16 Million USD | -1461.783% |
| Omega Therapeutics, Inc. | 128.42 Million USD | -47.899% |
| Quince Therapeutics, Inc. | 13.81 Million USD | -1275.011% |
| Rezolute, Inc. | 2.22 Million USD | -8425.314% |
| Clene Inc. | 32.16 Million USD | -490.604% |
| Indaptus Therapeutics, Inc. | 175.05 Thousand USD | -108406.567% |
| BeyondSpring Inc. | 3.99 Million USD | -4654.543% |
| Synlogic, Inc. | 17.27 Million USD | -999.531% |
| Allarity Therapeutics, Inc. | 1.3 Million USD | -14511.077% |
| Phio Pharmaceuticals Corp. | 35 Thousand USD | -542597.143% |
| Peak Bio, Inc. | 10.72 Million USD | -1671.567% |
| Werewolf Therapeutics, Inc. | 51.92 Million USD | -265.819% |
| Krystal Biotech, Inc. | 8.09 Million USD | -2246.726% |
| Karyopharm Therapeutics Inc. | 177.01 Million USD | -7.303% |
| SpringWorks Therapeutics, Inc. | 7.05 Million USD | -2591.569% |
| Lipella Pharmaceuticals Inc. | 136.59 Thousand USD | -138957.352% |
| MannKind Corporation | 382.37 Million USD | 50.326% |
| Ikena Oncology, Inc. | 10.73 Million USD | -1668.896% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 409 Thousand USD | -46341.076% |
| Gossamer Bio, Inc. | 212.46 Million USD | 10.599% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | 174 Thousand USD | -109063.218% |
| NRx Pharmaceuticals, Inc. | 9.16 Million USD | -1973.398% |
| Legend Biotech Corporation | 328.67 Million USD | 42.209% |
| Mural Oncology plc | 15 Million USD | -1165.534% |
| Biora Therapeutics, Inc. | 47.42 Million USD | -300.506% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Disc Medicine, Inc. | 2.1 Million USD | -8940.647% |
| Champions Oncology, Inc. | 7.43 Million USD | -2456.447% |
| REGENXBIO Inc. | 89.29 Million USD | -112.727% |
| Ensysce Biosciences, Inc. | 854.69 Thousand USD | -22123.548% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | 552.98 Thousand USD | -34249.038% |
| Edgewise Therapeutics, Inc. | 5.41 Million USD | -3408.386% |
| Vaxart, Inc. | 26.51 Million USD | -616.391% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | 15.65 Million USD | -1113.129% |
| Cellectis S.A. | 92.85 Million USD | -104.564% |
| Longeveron Inc. | 2.04 Million USD | -9206.418% |
| Repare Therapeutics Inc. | 3.41 Million USD | -5470.205% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 86.402% |
| Inozyme Pharma, Inc. | 46.59 Million USD | -307.675% |
| Revolution Medicines, Inc. | 87.94 Million USD | -115.983% |
| Nymox Pharmaceutical Corporation | 173 Thousand USD | -109694.22% |
| Third Harmonic Bio, Inc. | 3.95 Million USD | -4705.059% |
| ArriVent BioPharma, Inc. Common Stock | 317 Thousand USD | -59819.243% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 175 Thousand USD | -108439.429% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 76.504% |
| Denali Therapeutics Inc. | 52.24 Million USD | -263.592% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Veru Inc. | 14.4 Million USD | -1218.555% |
| Corvus Pharmaceuticals, Inc. | 1.37 Million USD | -13724.163% |
| Cingulate Inc. | 3.13 Million USD | -5958.628% |
| Passage Bio, Inc. | 26.29 Million USD | -622.385% |
| Context Therapeutics Inc. | - USD | -Infinity% |
| Exicure, Inc. | 6.66 Million USD | -2749.872% |
| Day One Biopharmaceuticals, Inc. | 408 Thousand USD | -46454.902% |
| Oramed Pharmaceuticals Inc. | 894 Thousand USD | -21146.532% |
| Scinai Immunotherapeutics Ltd. | 20.56 Million USD | -823.807% |
| Rhythm Pharmaceuticals, Inc. | 1.26 Million USD | -14974.921% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | 2.45 Million USD | -7649.271% |
| Carisma Therapeutics, Inc. | 3.12 Million USD | -5982.101% |
| Unicycive Therapeutics, Inc. | 811 Thousand USD | -23320.962% |
| OmniAb, Inc. | 25.56 Million USD | -643.101% |
| Anew Medical, Inc. | 1.6 Million USD | -11734.517% |
| Fennec Pharmaceuticals Inc. | 29.58 Million USD | -542.074% |
| Lipocine Inc. | 17.16 Thousand USD | -1106412.874% |
| Lexeo Therapeutics, Inc. Common Stock | 11.63 Million USD | -1532.102% |
| Nautilus Biotechnology, Inc. | 34.62 Million USD | -448.527% |
| SAB Biotherapeutics, Inc. | 5.9 Million USD | -3115.543% |
| G1 Therapeutics, Inc. | 57.17 Million USD | -232.227% |
| Bellerophon Therapeutics, Inc. | 203 Thousand USD | -93468.473% |
| Sage Therapeutics, Inc. | 5.16 Million USD | -3577.522% |
| Ocugen, Inc. | 6.94 Million USD | -2636.551% |
| Mind Medicine (MindMed) Inc. | 14.12 Million USD | -1244.356% |
| Q32 Bio Inc. | 1.31 Million USD | -14311.533% |
| Brainstorm Cell Therapeutics Inc. | 672 Thousand USD | -28165.476% |
| Alumis Inc. Common Stock | 32.58 Million USD | -483.008% |
| Equillium, Inc. | 824 Thousand USD | -22951.456% |
| Kyverna Therapeutics, Inc. | 9.07 Million USD | -1992.125% |
| Coya Therapeutics, Inc. | - USD | -Infinity% |
| CNS Pharmaceuticals, Inc. | 300.8 Thousand USD | -63045.017% |
| Galera Therapeutics, Inc. | 152.29 Million USD | -24.718% |
| Evelo Biosciences, Inc. | 51.13 Million USD | -271.434% |
| Comera Life Sciences Holdings, Inc. | 775.04 Thousand USD | -24407.385% |
| Dominari Holdings Inc. | 3.02 Million USD | -6172.919% |
| Edesa Biotech, Inc. | 94.48 Thousand USD | -200926.596% |
| vTv Therapeutics Inc. | 529 Thousand USD | -35806.238% |
| Bio-Techne Corporation | 419.53 Million USD | 54.725% |
| Agios Pharmaceuticals, Inc. | 71.99 Million USD | -163.826% |
| Harmony Biosciences Holdings, Inc. | 193.56 Million USD | 1.871% |
| Prelude Therapeutics Incorporated | 16.88 Million USD | -1024.728% |
| Candel Therapeutics, Inc. | 22.76 Million USD | -734.479% |
| iTeos Therapeutics, Inc. | 6.05 Million USD | -3035.424% |
| Nkarta, Inc. | 88.33 Million USD | -115.017% |
| BioCardia, Inc. | 1.31 Million USD | -14344.411% |
| Iterum Therapeutics plc | 19.5 Million USD | -873.622% |